BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33029258)

  • 21. Role of lncRNAs in prostate cancer development and progression.
    Weiss M; Plass C; Gerhauser C
    Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer.
    Zhang Z; Lee JH; Ruan H; Ye Y; Krakowiak J; Hu Q; Xiang Y; Gong J; Zhou B; Wang L; Lin C; Diao L; Mills GB; Li W; Han L
    Nat Commun; 2019 Oct; 10(1):4562. PubMed ID: 31594934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
    Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
    Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HeRA: an atlas of enhancer RNAs across human tissues.
    Zhang Z; Hong W; Ruan H; Jing Y; Li S; Liu Y; Wang J; Li W; Diao L; Han L
    Nucleic Acids Res; 2021 Jan; 49(D1):D932-D938. PubMed ID: 33119754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SELER: a database of super-enhancer-associated lncRNA- directed transcriptional regulation in human cancers.
    Guo ZW; Xie C; Li K; Zhai XM; Cai GX; Yang XX; Wu YS
    Database (Oxford); 2019 Jan; 2019():. PubMed ID: 30806704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.
    Wang D; Wan X; Zhang Y; Kong Z; Lu Y; Sun X; Huang Y; Ji C; Li D; Luo J; Gu W; Wang C; Li Y; Xu Y
    Prostate; 2019 Sep; 79(12):1362-1377. PubMed ID: 31269242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A four-enhancer RNA-based prognostic signature for thyroid cancer.
    Liang Y; Zhang Q; Xin T; Zhang DL
    Exp Cell Res; 2022 Mar; 412(2):113023. PubMed ID: 35033555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long non-coding RNA SNHG6 is upregulated in prostate cancer and predicts poor prognosis.
    Yan Y; Chen Z; Xiao Y; Wang X; Qian K
    Mol Biol Rep; 2019 Jun; 46(3):2771-2778. PubMed ID: 30911973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long non-coding RNAs in prostate cancer: Functional roles and clinical implications.
    Xu YH; Deng JL; Wang G; Zhu YS
    Cancer Lett; 2019 Nov; 464():37-55. PubMed ID: 31465841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DCP1A is an unfavorable prognostic-related enhancer RNA in hepatocellular carcinoma.
    Wu H; Zhang J; Bai Y; Zhang S; Zhang Z; Tong W; Han P; Fu B; Zhang Y; Shen Z
    Aging (Albany NY); 2021 Oct; 13(19):23020-23035. PubMed ID: 34609335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhancer RNAs: a class of long noncoding RNAs synthesized at enhancers.
    Kim TK; Hemberg M; Gray JM
    Cold Spring Harb Perspect Biol; 2015 Jan; 7(1):a018622. PubMed ID: 25561718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Advances on the Important Roles of Enhancer RNAs in Gene Regulation and Cancer.
    Liu Y; Ding M; Gao Q; He A; Liu Y; Mei H
    Biomed Res Int; 2018; 2018():2405351. PubMed ID: 29951530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging Roles of Long Non-coding RNAs as Novel Biomarkers in the Diagnosis and Prognosis of Prostate Cancer.
    Kan Y; Li B; Yang D; Liu Y; Liu J; Yang C; Mao L
    Discov Med; 2021; 32(165):29-37. PubMed ID: 35219354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
    Ramnarine VR; Kobelev M; Gibb EA; Nouri M; Lin D; Wang Y; Buttyan R; Davicioni E; Zoubeidi A; Collins CC
    Eur Urol; 2019 Nov; 76(5):546-559. PubMed ID: 31445843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases.
    Sattari M; Kohvakka A; Moradi E; Rauhala H; Urhonen H; Isaacs WB; Nykter M; Murtola TJ; Tammela TLJ; Latonen L; Bova GS; Kesseli J; Visakorpi T
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37140987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-coding Transcripts from Enhancers: New Insights into Enhancer Activity and Gene Expression Regulation.
    Chen H; Du G; Song X; Li L
    Genomics Proteomics Bioinformatics; 2017 Jun; 15(3):201-207. PubMed ID: 28599852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional annotation of structural ncRNAs within enhancer RNAs in the human genome: implications for human disease.
    Ren C; Liu F; Ouyang Z; An G; Zhao C; Shuai J; Cai S; Bo X; Shu W
    Sci Rep; 2017 Nov; 7(1):15518. PubMed ID: 29138457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of androgen response-related lncRNAs in prostate cancer.
    Karthikeyan SK; Xu N; Ferguson Rd JE; Rais-Bahrami S; Qin ZS; Manne U; Netto GJ; S Chandrashekar D; Varambally S
    Prostate; 2023 May; 83(6):590-601. PubMed ID: 36760203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long noncoding RNA in prostate, bladder, and kidney cancer.
    Martens-Uzunova ES; Böttcher R; Croce CM; Jenster G; Visakorpi T; Calin GA
    Eur Urol; 2014 Jun; 65(6):1140-51. PubMed ID: 24373479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological bases and clinical impact of long noncoding RNAs in prostate cancer: a new budding star.
    Xu T; Lin CM; Cheng SQ; Min J; Li L; Meng XM; Huang C; Zhang L; Deng ZY; Li J
    Mol Cancer; 2018 Jul; 17(1):103. PubMed ID: 30037351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.